Sector News

Nestle pushes further into health science with Seres investment

January 7, 2015
Life sciences
(Reuters) – Nestle Health Science has invested $65 million in U.S.-based drugmaker Seres Health Inc, the latest move by its parent company Nestle to diversify away from packaged food.
 
Nestle has been expanding its reach into the fast-growing market for healthcare products that have higher margins than the instant soups, breakfast cereals and coffee the world’s biggest food group is generally known for.
 
The investment will help fund the next stage of development of Seres’ lead product candidate against clostridium difficile infection (CDI) – a bacterial infection of the digestive system – into late-stage clinical trials and help advance its other treatments against infectious, metabolic and inflammatory diseases, Nestle said on Tuesday.
 
Nestle Health Science also said on Tuesday it had entered into a strategic partnership with Seres’ venture capital backer, Flagship Ventures, to support start-ups working on nutritional health and therapy in view of potential further minority direct investments, licensing deals, joint ventures or acquisitions.
 
Nestle set up Nestle Health Science in 2011 to develop new therapeutic approaches for gastrointestinal, metabolic and brain disorders and other health conditions.
 
(Reporting by Silke Koltrowitz; editing by Susan Thomas)

comments closed

Related News

May 21, 2022

As monkeypox cases emerge in US and Europe, Bavarian Nordic inks vaccine order

Life sciences

A monkeypox outbreak is emerging in the U.S. and Europe, and at least one country is amping up countermeasure preparedness. Bavarian Nordic has secured a contract with an unnamed European country to supply its smallpox vaccine, called Imvanex in Europe, in response to the emergence of monkeypox cases, the Danish company said Thursday.

May 21, 2022

Moderna chairman Afeyan defends hiring practices after CFO debacle: report

Life sciences

Moderna’s recent chief financial officer debacle—in which Jorge Gomez departed on his second day on the job—raised questions about the company’s hiring process given its rush to global biopharma prominence. The most obvious one: How was it possible for Gomez to be hired when he was under investigation by his previous employer, Dentsply Sirona of Charlotte, N.C.

May 21, 2022

Merck to pay up to $1.4B in cancer deal with Kelun, but details are scarce

Life sciences

Merck & Co. is plucking a cancer project from the branch of Chinese-based Kelun Pharmaceutical for up to $1.4 billion, but details from the New Jersey-based Big Pharma have been hard to come by. The deal, first disclosed Monday on the Shenzhen stock exchange, has Merck handing over $47 million in upfront cash in exchange for ex-China rights to a “macromolecular tumor project.”